Table A.9.

Distributions of doses taken by clinical trial participants¹ for each regimen (9H and 3HP)^*

3HP			9H
Doses taken	Patients %	Cumulative %	Months on treatment	Patients %	Cumulative %
0	2.53	2.53	1	9.42	9.42
1	2.39	4.92	2	3.76	13.18
2	1.83	6.76	3	3.66	16.84
3	2.39	9.14	4	2.69	19.52
4	2.29	11.44	5	2.53	22.06
5	1.47	12.91	6	2.20	24.26
6	1.13	14.04	7	1.87	26.13
7	1.09	15.13	8	5.42	31.55
8	1.18	16.31	9	66.89	98.44
9	0.63	16.94	10	1.56	100.00
10	0.29	17.23
11	1.91	19.13
12	80.63	99.76
13	0.22	99.98
14	0.00	99.98
15	0.00	99.98
16	0.00	99.98
17	0.02	100.00

^*Data from the Tuberculosis Trials Consortium Data Coordinating Center.

9H = 9 months of daily, self-administered isoniazid; 3HP = 12-dose regimen of weekly rifapentine plus isoniazid.